CD8A and hepatocellular carcinoma: One prospective, non-randomized study demonstrated that RFA, TACE, and chemoablation (CA) stimulated a CD8 T cell response and increased the efficacy of the ICI tremelimumab (anti-CTLA-4 mAb) in patients with advanced-stage HCC.